查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球疫苗市場：2024年
市場調查報告書
商品編碼
1431793

全球疫苗市場：2024年

The World Market for Vaccines, 2024
出版日期: | 出版商: Kalorama Information | 英文 202 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

疫苗提供針對疾病的長期或永久免疫力。70 多年來，疫苗一直是預防醫學的基石，可刺激針對特定疾病的免疫反應。有效疫苗的廣泛普及幾乎消除了許多致命疾病，使疫苗接種成為 20 世紀最偉大的公共衛生成就之一。

由於公共免疫計劃，疫苗可預防的疾病和相關死亡現在在已開發國家很少見，並且在全球範圍內正在下降。天花已被消滅，小兒麻痺已在美洲消滅，麻疹、德國麻疹、破傷風、白喉、B型流感嗜血桿菌等疾病已被控制。除了預防疾病和死亡之外，疫苗還可以提高生活品質和生產力。它透過預防疾病爆發和降低醫療成本提供了顯著的社會效益。

該報告考察了全球疫苗市場，並對成人和兒童預防疫苗進行了最新、全面的分析。我們還調查疫苗類別的市場預測、公司股票數據、專家的市場預測以及用於預防各種疾病的人類疫苗的市場趨勢。我們特別關注那些已經可以透過疫苗預防的疾病，包括商業上可用的和正在開發的疾病。

目錄

第一章執行摘要

第二章 疫苗簡介

  • 介紹
  • 傳記：疫苗開發
  • 人體免疫系統
  • 疫苗作用機制
  • 疫苗類型
  • 減毒（減毒）活病毒
  • 死（滅活）病毒
  • 類毒素疫苗
  • 基因重組/改良疫苗
  • 亞單位疫苗
  • 結合疫苗
  • 脫氧核糖核酸疫苗
  • 信使RNA疫苗
  • 重組載體疫苗
  • 疫苗的分類
  • 疫苗審批流程
  • FDA EUA 批准
  • 世界衛生組織認證的疫苗
  • 大流行
  • HIN1 2009/2010 年大流行
  • 冠狀病毒大流行
  • 伊波拉出血熱爆發
  • 製造業激勵措施
  • 合成疫苗
  • 人工智慧發展

第三章 兒童預防疫苗

  • 介紹
  • 美國的兒童免疫接種
  • 兒童免疫接種率
  • 疫苗輸送系統面臨的挑戰
  • 建議的兒童免疫計劃
  • 各州的免疫接種建議
  • COVID-19 疫苗接種時間表
  • 聯合國的努力
  • 兒科疫苗市場
  • 競爭概況

第四章 成人預防疫苗

  • 介紹
  • 建議的成人免疫接種
  • 全球流感監測計劃
  • 美國監視
  • 世界衛生組織 國際衛生條例
  • 成人預防疫苗市場
  • 市場：佔成人非 COVID-19 疫苗總銷量的 26%
  • 流感
  • 競爭概況

第五章疫苗整體市場

  • 推動疫苗市場的趨勢
  • 市場規模及預測
  • 兒科疫苗
  • 成人疫苗
  • 估計並預測 COVID-19 市場規模
  • 各地區疫苗銷售狀況
  • 世界其他地區
  • 美國
  • 歐洲
  • 疫苗市場的競爭對手
  • 疫苗產業新聞
  • 正在開發的疫苗
  • COVID-19 疫苗開發

第六章 公司簡介

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE
簡介目錄
Product Code: 24-012

Vaccines offer long-term or permanent immunity against diseases. They have been a cornerstone of preventive medicine for over 70 years, stimulating an immune response to specific diseases. The widespread adoption of effective vaccines has led to the near-elimination of many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century.

Thanks to public vaccination programs, vaccine-preventable diseases and related deaths are now rare in developed nations and decreasing globally. Smallpox has been eradicated, polio eliminated in the Americas, and diseases like measles, rubella, tetanus, diphtheria, and Haemophilus influenzae type b controlled. Beyond preventing illness and death, vaccines also improve quality of life and productivity. They help prevent disease outbreaks and reduce healthcare costs, providing significant societal benefits.

Kalorama Information's latest report, "The World Market for Vaccines, 2024", offers the most up-to-date and comprehensive analysis of adult and pediatric preventative vaccines. Since the early 2000s, Kalorama has consistently published new editions of The World Market for Vaccines every two years. The report includes market forecasts, company market share data, and expert market estimates for different vaccine categories.

"The World Market for Vaccines, 2024" also examines market trends for human vaccines used to prevent various diseases. It specifically focuses on both commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable. Additionally, the report discusses selected emerging vaccines in development.

Vaccines covered in the report with sizing and market share include:

  • Combinations (tetanus, pertussis, Hib, Hepatitis, polio)
  • Hepatitis
  • HPV
  • Influenza
  • Meningitis
  • Pandemic vaccines/COVID-19
  • Pneumococcal
  • Rotavirus
  • RSV
  • Shingles
  • Others (travel, endemic, etc.)

The report also examines key companies involved in the market. Companies profiled in the report include:

  • AstraZeneca
  • Bavarian Nordic, A/S
  • Bharat Biotech International Ltd.
  • Bio Farma
  • BioNTech SE
  • CSL Limited/Seqirus
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson/Crucell/Janssen
  • Merck & Co, Inc.
  • Moderna, Inc
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi Pasteur
  • Serum Institute, Inc.
  • Sinovac Biotech Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Co, Ltd.
  • Valneva SE

Scope and Methodology

"The World Market for Vaccines, 2024" examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends and form the basis of the forecasting and competitive analysis.

It should also be noted that due to the very broad scope of this report, with the exception of healthcare spending forecasts, data provided is representative but is not intended to be exhaustive. This includes, for example, tables of vaccines in development and regional economic indicators, etc. Additionally, some statistics, such as those related to venture capital investment, are subject to wide divergences across different sources; where data could not be confidently obtained, trends were discussed rather than absolute numerical values.

Table of Contents

Chapter 1: Executive Summary

  • The Global Vaccines Industry
  • Scope and Methodology
  • Market Estimates and Forecasts
    • Figure 1-1: Global Vaccine Market (Non-COVID Vaccine Market; COVID Vaccine Market), 2023-2028 ($M)
    • Figure 1-2: Regional Non-COVID vs COVID Vaccine Markets, 2018-2028 ($)
  • Competitive Analysis

Chapter 2: Introduction to Vaccines

  • Introduction
    • Table 2-1: Global Reported Cases of Vaccine Preventable Diseases, 2000 vs. 2022
    • Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
  • A Brief History: The Development of Vaccines
  • The Human Immune System
  • Vaccine Mechanism of Action
  • Types of Vaccines
  • Attenuated (Weakened) Live Viruses
    • Figure 2-2: Attenuated Virus Production
  • Killed (Inactivated) Viruses
  • Toxoid Vaccines
  • Genetically Engineered/Modified Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • DNA Vaccines
  • Messenger RNA Vaccines
  • Recombinant Vector Vaccines
  • Classification of Vaccines
  • Vaccine Approval Process
    • Figure 2-3: Global Vaccine Sales by Region, 2023
  • FDA EUA Approval
  • World Health Organization Prequalified Vaccines
    • Table 2-3: WHO Prequalified BCG Vaccines
    • Table 2-4: WHO Prequalified Cholera Vaccines
    • Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
    • Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
    • Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
    • Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
    • Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
    • Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
    • Table 2-11: WHO Prequalified Hepatitis A Vaccines
    • Table 2-12: WHO Prequalified Hepatitis B Vaccines
    • Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
    • Table 2-14: WHO Prequalified Influenza Vaccines
    • Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
    • Table 2-16: WHO Prequalified Measles Vaccines
    • Table 2-17: WHO Prequalified Measles and Rubella Vaccines
    • Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
    • Table 2-19: WHO Prequalified Meningococcal A Vaccines
    • Table 2-20: WHO Prequalified Pneumococcal Vaccines
    • Table 2-21: WHO Prequalified Polio Vaccines
    • Table 2-22: WHO Prequalified Rabies Vaccines
    • Table 2-23: WHO Prequalified Rotavirus Vaccines
    • Table 2-24: WHO Prequalified Rubella Vaccines
    • Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
    • Table 2-26: WHO Prequalified Typhoid Vaccines
    • Table 2-27: WHO Prequalified Varicella Vaccine
    • Table 2-28: WHO Prequalified Yellow Fever Vaccines
    • Table 2-29: WHO Prequalified Other Vaccines
  • Pandemics
  • HIN1 Pandemic of 2009/2010
  • Coronavirus Pandemic
    • Figure 2-4: Leading COVID-19 Vaccines: Supplied Dose Estimates
  • Ebola Epidemics
  • Manufacturing Incentives
  • Synthetic Vaccines
  • Artificial Intelligence Development

Chapter 3: Pediatric Preventative Vaccines

  • Introduction
    • Table 3-1: Immunization Rates for Vaccines Recommended by the WHO, 2022
  • Childhood Immunization in the United States
  • Childhood Immunization Rates
  • Challenges to the Vaccine Delivery System
  • Recommended Childhood Immunization Schedule
    • Figure 3-1: CDC Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024
    • Figure 3-2: CDC Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024
  • State Immunization Recommendations
    • Figure 3-3: Exemptions Permitted for State Childcare and School (Grades PreK-12) Immunization Requirements, United States, March 2023
  • COVID-19 Vaccination Schedule
  • United Nations Initiatives
  • Pediatric Vaccine Markets
    • Table 3-2: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 ($M)
    • Figure 3-4: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023-2028 (%)
    • Figure 3-5: Market Share of Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023 (%)
  • Competitive Summary
    • Table 3-3: Major Manufacturers' Shares of the Global Pediatric Preventative Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 3-6: Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023, (%)

Chapter 4: Adult Preventative Vaccines

  • Introduction
  • Recommended Adult Immunizations
    • Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
  • Global Influenza Surveillance Program
  • U.S. Surveillance
    • Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004-2023 (%)
    • Figure 4-2: U.S. Influenza Vaccine Effectiveness, by Season, 2009-2023, (%)
  • WHO International Health Regulations
  • Adult Preventive Vaccine Markets
    • Table 4-2: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023-2028 ($M)
    • Figure 4-3: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other), 2023-2028 (%)
    • Figure 4-4: Market Share of Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023 (%)
  • Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
    • Figure 4-5: U.S. Seasonal Influenza Vaccination, by Age Group and Season, 2010-2023 (%)
    • Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target - Total Population - Seasons, 2010-2023 (%)
  • Influenza
    • Figure 4-7: Estimated U.S. Flu Burden, by Season 2010-2023
    • Table 4-3: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-4: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-5: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Table 4-6: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group - United States, 2022-2023 Influenza Season
    • Figure 4-8: Estimated U.S. Flu Burden Prevented by Vaccination (Deaths, Hospitalizations, Medical Visits, Symptomatic Illness), 2010-2023
    • Table 4-7: WHO Pandemic Classification Schedule
  • Competitive Summary
    • Table 4-8: Major Manufacturers' Shares of the Global Adult Preventative Vaccine Market, by Company (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
    • Figure 4-9: Global Adult Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%)

Chapter 5: Total Vaccines Market

  • Trends Driving the Vaccines Market
    • Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
  • Market Size and Forecast
    • Table 5-1: Total Global Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
    • Figure 5-2: Total World Market for Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]),, 2023-2028 (Pediatric, Adult) (SM)
    • Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2023-2028 ($M)
  • Pediatric Vaccines
  • Adult Vaccines
    • Figure 5-4: Global Preventive Vaccine Market, by Broad Segment (Pediatric, Adult), Trend 2018-2028 ($M)
  • COVID-19 Market Size Estimates and Forecast
    • Table 5-2: Global COVID-19 Vaccine Market Cumulative Value, 2020-2023 ($M)
    • Figure 5-5: Global COVID-19 Vaccine by Unit Volume, Cumulative 2020-2023, Estimated Distribution by Country (Australia, Brazil, Canada, China, European Union, India, Japan, Russia, South Africa, South Korea, United States, Other Countries)
  • Vaccine Sales by Region
  • Rest of World
    • Table 5-3: Total ROW Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • United States
    • Table 5-4: Total U.S. Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Europe
    • Table 5-5: Total Europe Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023-2028 ($M)
  • Vaccine Market Competitors
    • Table 5-6: Major Manufacturers' Shares of the Global Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%, $M)
    • Figure 5-6: Global Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%)
  • Vaccine Industry News
  • Vaccines in Development
  • COVID-19 Vaccine Development
    • Figure 5-7: Regional Distribution of COVID-19 Vaccine Development, by Country and Region (Australia, Brazil, Canada, China, France, Indonesia, Japan, Mexico, Middle East, Philippines, Rest of Africa, Rest of Pacific, Rest of Europe, Rest of Latin America, South Africa, South Korea, United Kingdom, United States)
    • Table 5-7: Selected Vaccines in Development, 2023

Chapter 6: Company Profiles

  • AstraZeneca
    • Table 6-1: AstraZeneca Corporate Summary
      • Company Summary
      • Products
  • Bavarian Nordic, A/S
    • Table 6-2: Bavarian Nordic A/S Corporate Summary
      • Company Summary
      • Products
  • Bharat Biotech International Ltd.
    • Table 6-3: Bharat Biotech Corporate Summary
      • Company Summary
      • Products
  • Bio Farma
    • Table 6-4: Bio Farma Corporate Summary
      • Company Summary
      • Products
  • BioNTech SE
    • Table 6-5: BioNTech Corporate Summary
      • Company Summary
      • Products
  • CSL Limited/Seqirus
    • Table 6-6: CSL/Seqirus Corporate Summary
      • Company Summary
      • Products
  • Dynavax Technologies
    • Table 6-7: Dynavax Technologies Corporate Summary
      • Company Summary
      • Products
  • Emergent BioSolutions, Inc.
    • Table 6-8: Emergent BioSolutions Corporate Summary
      • Company Summary
      • Products
  • GlaxoSmithKline, Inc.
    • Table 6-9: GlaxoSmithKline Corporate Summary
      • Company Summary
      • Products
    • Table 6-10: GSK Marketed Vaccines, 2024
  • Inovio Pharmaceuticals, Inc.
    • Table 6-11: Inovio Corporate Summary
      • Company Summary
      • Products
  • Johnson & Johnson/Crucell/Janssen
    • Table 6-12: Johnson & Johnson Corporate Summary
      • Company Summary
      • Products
  • Merck & Co, Inc.
    • Table 6-13: Merck Corporate Summary
      • Company Summary
      • Products
  • Moderna, Inc.
    • Table 6-14: Moderna Corporate Summary
      • Company Summary
      • Products
  • Novavax, Inc.
    • Table 6-15: Novavax Corporate Summary
      • Company Summary
      • Products
  • Pfizer, Inc.
    • Table 6-16: Pfizer Corporate Summary
      • Company Summary
      • Products
  • Sanofi Pasteur
    • Table 6-17: Sanofi Pasteur Corporate Summary
      • Company Summary
      • Products
  • Serum Institute, Inc.
    • Table 6-18: Serum Institute of India Corporate Summary
      • Company Summary
      • Products
  • Sinovac Biotech Ltd.
    • Table 6-19: Sinovac Biotech Corporate Summary
      • Company Summary
      • Products
  • Soligenix, Inc.
    • Table 6-20: Soligenix Corporate Summary
      • Company Summary
      • Products
  • Takeda Pharmaceutical Co, Ltd.
    • Table 6-21: Takeda Pharmaceutical Corporate Summary
      • Company Summary
      • Products
  • Valneva SE
    • Table 6-22: Valneva Corporate Summary
      • Company Summary
      • Products